Chronic Lymphocytic Leukemia Treatment

Researchers in New York have determined that a combination of rituximab and idelalisib is effective in limiting the progression of chronic lymphocytic leukemia (CLL).  In fact, the positive effects shown in this study were so compelling that the study was halted and the treatment was prescribed for all of the patients in the study.  The combination of drugs may allow CLL patients to avoid repeated chemotherapy regimens and the harsh side effects of such treatments.  An article discussing the study can be found at

Speak Your Mind